IL-17+ regulatory T cells in the microenvironments of chronic inflammation and cancer - PubMed (original) (raw)
. 2011 Apr 1;186(7):4388-95.
doi: 10.4049/jimmunol.1003251. Epub 2011 Feb 28.
Ke Wu, Ende Zhao, Shuang Wei, Linhua Vatan, Wojciech Szeliga, Emina Huang, Joel Greenson, Alfred Chang, Jacek Roliński, Piotr Radwan, Jingyuan Fang, Guobin Wang, Weiping Zou
Affiliations
- PMID: 21357259
- DOI: 10.4049/jimmunol.1003251
IL-17+ regulatory T cells in the microenvironments of chronic inflammation and cancer
Ilona Kryczek et al. J Immunol. 2011.
Abstract
Foxp3(+)CD4(+) regulatory T (Treg) cells inhibit immune responses and temper inflammation. IL-17(+)CD4(+) T (Th17) cells mediate inflammation of autoimmune diseases. A small population of IL-17(+)Foxp3(+)CD4(+) T cells has been observed in peripheral blood in healthy human beings. However, the biology of IL-17(+)Foxp3(+)CD4(+) T cells remains poorly understood in humans. We investigated their phenotype, cytokine profile, generation, and pathological relevance in patients with ulcerative colitis. We observed that high levels of IL-17(+)Foxp3(+)CD4(+) T cells were selectively accumulated in the colitic microenvironment and associated colon carcinoma. The phenotype and cytokine profile of IL-17(+)Foxp3(+)CD4(+) T cells was overlapping with Th17 and Treg cells. Myeloid APCs, IL-2, and TGF-β are essential for their induction from memory CCR6(+) T cells or Treg cells. IL-17(+)Foxp3(+)CD4(+) T cells functionally suppressed T cell activation and stimulated inflammatory cytokine production in the colitic tissues. Our data indicate that IL-17(+)Foxp3(+) cells may be "inflammatory" Treg cells in the pathological microenvironments. These cells may contribute to the pathogenesis of ulcerative colitis through inducing inflammatory cytokines and inhibiting local T cell immunity, and in turn may mechanistically link human chronic inflammation to tumor development. Our data therefore challenge commonly held beliefs of the anti-inflammatory role of Treg cells and suggest a more complex Treg cell biology, at least in the context of human chronic inflammation and associated carcinoma.
Similar articles
- Increased CD4+CD45RA-FoxP3low cells alter the balance between Treg and Th17 cells in colitis mice.
Ma YH, Zhang J, Chen X, Xie YF, Pang YH, Liu XJ. Ma YH, et al. World J Gastroenterol. 2016 Nov 14;22(42):9356-9367. doi: 10.3748/wjg.v22.i42.9356. World J Gastroenterol. 2016. PMID: 27895423 Free PMC article. - Increased prevalence of circulating novel IL-17 secreting Foxp3 expressing CD4+ T cells and defective suppressive function of circulating Foxp3+ regulatory cells support plasticity between Th17 and regulatory T cells in inflammatory bowel disease patients.
Ueno A, Jijon H, Chan R, Ford K, Hirota C, Kaplan GG, Beck PL, Iacucci M, Fort Gasia M, Barkema HW, Panaccione R, Ghosh S. Ueno A, et al. Inflamm Bowel Dis. 2013 Nov;19(12):2522-34. doi: 10.1097/MIB.0b013e3182a85709. Inflamm Bowel Dis. 2013. PMID: 24097227 - Expression and functional characterization of FOXP3+ CD4+ regulatory T cells in ulcerative colitis.
Yu QT, Saruta M, Avanesyan A, Fleshner PR, Banham AH, Papadakis KA. Yu QT, et al. Inflamm Bowel Dis. 2007 Feb;13(2):191-9. doi: 10.1002/ibd.20053. Inflamm Bowel Dis. 2007. PMID: 17206665 - Origin and functions of pro-inflammatory cytokine producing Foxp3+ regulatory T cells.
Pandiyan P, Zhu J. Pandiyan P, et al. Cytokine. 2015 Nov;76(1):13-24. doi: 10.1016/j.cyto.2015.07.005. Epub 2015 Jul 10. Cytokine. 2015. PMID: 26165923 Free PMC article. Review. - IL-17+Foxp3+ T cells: an intermediate differentiation stage between Th17 cells and regulatory T cells.
Du R, Zhao H, Yan F, Li H. Du R, et al. J Leukoc Biol. 2014 Jul;96(1):39-48. doi: 10.1189/jlb.1RU0114-010RR. Epub 2014 Apr 17. J Leukoc Biol. 2014. PMID: 24744433 Review.
Cited by
- Th17/Treg cell balance in patients with papillary thyroid carcinoma: a new potential biomarker and therapeutic target.
Huo MH, Adeerjiang Y, Abulitipu A, Khan U, Li XX, Zhang L, Tian Y, Jiang S, Xu CC, Chao XZ, Yang YF, Zhang JX, Du GL. Huo MH, et al. Front Oncol. 2024 Oct 29;14:1325575. doi: 10.3389/fonc.2024.1325575. eCollection 2024. Front Oncol. 2024. PMID: 39534095 Free PMC article. Review. - Th17 cell function in cancers: immunosuppressive agents or anti-tumor allies?
Anvar MT, Rashidan K, Arsam N, Rasouli-Saravani A, Yadegari H, Ahmadi A, Asgari Z, Vanan AG, Ghorbaninezhad F, Tahmasebi S. Anvar MT, et al. Cancer Cell Int. 2024 Oct 27;24(1):355. doi: 10.1186/s12935-024-03525-9. Cancer Cell Int. 2024. PMID: 39465401 Free PMC article. Review. - Narciclasine induces colon carcinoma cell apoptosis by inhibiting the IL-17A/Act1/TRAF6/NF-κB signaling pathway.
Deng H, Liu Q, Yu S, Zhong L, Gan L, Gu H, Wang Q, Cheng R, Liu Y, Liu L, Huang L, Xu R. Deng H, et al. Genes Dis. 2023 Apr 13;11(5):100938. doi: 10.1016/j.gendis.2023.03.014. eCollection 2024 Sep. Genes Dis. 2023. PMID: 39071112 Free PMC article. - Regulatory T Cell Dysfunction in Autoimmune Diseases.
Honing DY, Luiten RM, Matos TR. Honing DY, et al. Int J Mol Sci. 2024 Jun 29;25(13):7171. doi: 10.3390/ijms25137171. Int J Mol Sci. 2024. PMID: 39000278 Free PMC article. Review. - Tissue adaptation of CD4 T lymphocytes in homeostasis and cancer.
Pereira MVA, Galvani RG, Gonçalves-Silva T, de Vasconcelo ZFM, Bonomo A. Pereira MVA, et al. Front Immunol. 2024 Apr 16;15:1379376. doi: 10.3389/fimmu.2024.1379376. eCollection 2024. Front Immunol. 2024. PMID: 38690280 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
- CA099985/CA/NCI NIH HHS/United States
- CA133620/CA/NCI NIH HHS/United States
- R01 CA142808/CA/NCI NIH HHS/United States
- 5 P30 CA46592/CA/NCI NIH HHS/United States
- CA123088/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous